Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy

Modulating IgG effector function by Fc glycan engineering

(2017) Tiezheng Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

An Fc Double-Engineered CD20 Antibody with Enhanced Ability to Trigger Complement-Dependent Cytotoxicity and Antibody-Dependent Cell-Mediated Cytotoxicity

(2017) Tim Wirt et al.   TRANSFUSION MEDICINE AND HEMOTHERAPY

Atezolizumab: A PD-L1–Blocking Antibody for Bladder Cancer

(2016) Brant A. Inman et al.   CLINICAL CANCER RESEARCH

An Fc-optimized CD133 antibody for induction of NK cell reactivity against myeloid leukemia

(2016) S P Koerner et al.   LEUKEMIA

Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies

(2016) Marco Thomann et al.   MOLECULAR IMMUNOLOGY

A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface

(2016) Rob N. de Jong et al.   PLOS BIOLOGY

Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity

(2015) Isaak Quast et al.   JOURNAL OF CLINICAL INVESTIGATION

Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study

(2015) Laurie H. Sehn et al.   JOURNAL OF CLINICAL ONCOLOGY

A Monosaccharide Residue Is Sufficient to Maintain Mouse and Human IgG Subclass Activity and Directs IgG Effector Functions to Cellular Fc Receptors

(2015) Daniela Kao et al.   Cell Reports

IgGA: A “Cross-Isotype” Engineered Human Fc Antibody Domain that Displays Both IgG-like and IgA-like Effector Functions

(2014) William Kelton et al.   CHEMISTRY & BIOLOGY

U.S. Food and Drug Administration Approval: Obinutuzumab in Combination with Chlorambucil for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia

(2014) H.-Z. Lee et al.   CLINICAL CANCER RESEARCH

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

(2014) Valentin Goede et al.   NEW ENGLAND JOURNAL OF MEDICINE

Complement Is Activated by IgG Hexamers Assembled at the Cell Surface

(2014) C. A. Diebolder et al.   SCIENCE

The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients

(2013) C Kellner et al.   LEUKEMIA

Increasing FcγRIIa affinity of an FcγRIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicity

(2013) Stefanie Derer et al.   mAbs

An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations

(2013) Omid Vafa et al.   METHODS

Antibody-Based Immunotherapy of Cancer

(2012) Louis M. Weiner et al.   CELL

Marketing approval of mogamulizumab

(2012) Alain Beck et al.   mAbs

Marketed therapeutic antibodies compendium

(2012) Janice M. Reichert   mAbs

Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fc  receptor engagement

(2012) F. Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CHO-gmt5, a novel CHO glycosylation mutant for producing afucosylated and asialylated recombinant antibodies

(2012) Ryan Haryadi et al.   Bioengineered

Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism

(2011) S. Veeramani et al.   BLOOD

An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells

(2011) Nicholas S. Wilson et al.   CANCER CELL

Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans

(2011) Tsunehiro Mizushima et al.   GENES TO CELLS

The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden

(2011) P. Boross et al.   HAEMATOLOGICA

Monocyte Subsets Responsible for Immunoglobulin G-Dependent Effector Functions In Vivo

(2011) Markus Biburger et al.   IMMUNITY

Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC

(2011) Roland Repp et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Interaction with Fc RIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody

(2011) A. L. White et al.   JOURNAL OF IMMUNOLOGY

Unique carbohydrate-carbohydrate interactions are required for high affinity binding between Fc RIII and antibodies lacking core fucose

(2011) C. Ferrara et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inhibitory Fc  Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies

(2011) F. Li et al.   SCIENCE

In vivo Cytotoxicity of Type I CD20 Antibodies Critically Depends on Fc Receptor ITAM Signaling

(2010) S. de Haij et al.   CANCER RESEARCH

Production of non-fucosylated antibodies by co-expression of heterologous GDP-6-deoxy-D-lyxo-4-hexulose reductase

(2010) H. H. von Horsten et al.   GLYCOBIOLOGY

Enhancing the action of rituximab by adding fresh frozen plasma for the treatment of fludarabine refractory chronic lymphocytic leukemia

(2010) Wei Xu et al.   INTERNATIONAL JOURNAL OF CANCER

Engineering host cell lines to reduce terminal sialylation of secreted antibodies

(2010) Michael F. Naso et al.   mAbs

Rapid production of recombinant human IgG With improved ADCC effector function in a transient expression system

(2009) Patrick H.C. van Berkel et al.   BIOTECHNOLOGY AND BIOENGINEERING

Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model

(2009) S.-Y. Wang et al.   BLOOD

Optimization of Fc-mediated effector functions of monoclonal antibodies

(2009) William R Strohl   CURRENT OPINION IN BIOTECHNOLOGY

Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcγRIIIb and MHC class II expression on the phagocytotic neutrophils

(2009) Mami Shibata-Koyama et al.   EXPERIMENTAL HEMATOLOGY

Structure of the Murine Unglycosylated IgG1 Fc Fragment

(2009) Matthias J. Feige et al.   JOURNAL OF MOLECULAR BIOLOGY

Monoclonal antibodies for cancer immunotherapy

(2009) Louis M Weiner et al.   LANCET

Glycosylation as a strategy to improve antibody-based therapeutics

(2009) Roy Jefferis   NATURE REVIEWS DRUG DISCOVERY

Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells

(2008) M. Peipp et al.   BLOOD

Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20

(2008) D. Dayde et al.   BLOOD

The impact of Fc engineering on an anti-CD19 antibody: increased Fc  receptor affinity enhances B-cell clearing in nonhuman primates

(2008) J. Zalevsky et al.   BLOOD

Engineered Antibodies of IgG1/IgG3 Mixed Isotype with Enhanced Cytotoxic Activities

(2008) A. Natsume et al.   CANCER RESEARCH

Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia

(2008) H. M. Horton et al.   CANCER RESEARCH

Terminal sugars of Fc glycans influence antibody effector functions of IgGs

(2008) T Shantha Raju   CURRENT OPINION IN IMMUNOLOGY

Molecular engineering and design of therapeutic antibodies

(2008) Leonard G Presta   CURRENT OPINION IN IMMUNOLOGY

Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer

(2008) Antonino Musolino et al.   JOURNAL OF CLINICAL ONCOLOGY